Clinical Trials on Primary Sclerosing Cholangitis in Australia

Total 2241 results

HighTide Biopharma Pty Ltd

Completed

A Study of HTD1801 in Healthy Subjects

Primary Sclerosing Cholangitis

Australia
Dr. Falk Pharma GmbH

Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Primary Sclerosing Cholangitis

Austria, Germany
Dr. Falk Pharma GmbH

Completed

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3)

Primary Sclerosing Cholangitis

Austria, Germany, Norway
Pliant Therapeutics, Inc.

Completed

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis

United States, Belgium, Australia, Canada, Netherlands, Germany, Austria, United Kingdom, France
Medical University of Graz

Active, not recruiting

Secondary Sclerosing Cholangitis in Critically Ill Patients (SSC-CIP)

Secondary Sclerosing Cholangitis

Austria
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
Gilead Sciences

Terminated

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis (PRIMIS)

Primary Sclerosing Cholangitis

United States, Belgium, Israel, Spain, United Kingdom, Australia, Germany, New Zealand, Denmark, France, Japan, Switzerland, Austria, Canada, Finland, Italy
Medical University of Graz

Recruiting

Secondary Sclerosis Cholangitis Prospective (SSCpro)

Secondary Sclerosis Cholangitis in Critically Ill Patients

Austria
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

Primary Biliary Cholangitis | Liver Stiffness

United States, Spain, France, Australia, Israel, Canada, Switzerland, Italy, New Zealand, Germany, Poland, Greece, United Kingdom, Belgium, Austria, Czechia, Hungary, Sweden
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
GlaxoSmithKline

Completed

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Cholestasis

United States, Australia, France, Spain, Germany, Canada, Japan, United Kingdom, Italy, Poland
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Biogen

Completed

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta (RENeu)

Relapsing-Remitting Multiple Sclerosis

New Zealand, Australia
Innate Immunotherapeutics
Syneos Health

Completed

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

New Zealand, Australia
Biogen

Terminated

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (TODAY)

Relapsing Remitting Multiple Sclerosis

Australia
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (P1A114919)

Multiple Sclerosis, Relapsing-Remitting

Australia
GlaxoSmithKline

Completed

Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (P1A114347)

Multiple Sclerosis, Relapsing-Remitting

Australia
Implicit Bioscience

Withdrawn

IC14 for Treatment of Amyotrophic Lateral Sclerosis

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Implicit Bioscience
Royal Brisbane and Women's Hospital

Completed

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
CSL Behring

Completed

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis

Australia, Germany, Poland, Italy, United Kingdom
Implicit Bioscience

Withdrawn

IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Australia
University of Melbourne

Active, not recruiting

An Online Lifestyle Modification Course for People With Multiple Sclerosis

Multiple Sclerosis

Australia
GlaxoSmithKline

Terminated

NOGO-A in Multiple Sclerosis FTIH

Multiple Sclerosis

Australia
Novartis Pharmaceuticals

Completed

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Secondary Progressive Multiple Sclerosis

Australia
Spinogenix
Novotech (Australia) Pty Limited

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants

Amyotrophic Lateral Sclerosis

Australia
Monash University

Enrolling by invitation

Relationship Between Oral DMT Burden and Adherence in MS (STATURE)

Multiple Sclerosis | Adherence, Medication

Australia
Gold Coast Hospital and Health Service
Bod Australia

Active, not recruiting

Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
Collaborative Medicinal Development Pty Limited

Active, not recruiting

ALS Treatment Extension Study

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Unknown

CuATSM Compared With Placebo for Treatment of ALS/MND

Amyotrophic Lateral Sclerosis

Australia
Clene Nanomedicine
Clene Australia Pty Ltd

Completed

Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) (RESCUE-ALS)

Amyotrophic Lateral Sclerosis

Australia
Melbourne Health
Eastern Health

Completed

The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor

Multiple Sclerosis | Tremor

Australia
Novartis Pharmaceuticals

Completed

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis (TIMIOS)

Relapsing Forms of Multiple Sclerosis

Australia, United States
Pipeline Therapeutics, Inc.

Completed

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

Multiple Sclerosis

Australia
Macquarie University, Australia
King's College London; Stichting TRICALS Foundation

Recruiting

Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

Amyotrophic Lateral Sclerosis

Australia, New Zealand
Pfenex, Inc

Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Multiple Sclerosis

Australia
Macquarie University, Australia
ZZ Biotech, LLC

Completed

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Completed

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Amyotrophic Lateral Sclerosis

Australia
University of Melbourne
Monash University; Western Sydney Local Health District; Royal Prince Alfred... and other collaborators

Recruiting

Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease (3TLA)

Motor Neuron Disease / Amyotrophic Lateral Sclerosis

Australia
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
The Florey Institute of Neuroscience and Mental...
The University of Queensland; Mobius Medical Pty Ltd.

Recruiting

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS (AMBALS)

Amyotrophic Lateral Sclerosis

Australia
GlaxoSmithKline

Completed

Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.

Multiple Sclerosis, Relapsing-Remitting

Australia

Clinical Trials on Primary Sclerosing Cholangitis in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations